Deluccia Robert J's Form 4 filing
Acurx Pharmaceuticals, Inc. (ACXP) · filed Nov 22, 2021
- Accession no.
- 0001104659-21-142473
- Filed
- Nov 22, 2021
- Trade date
- Nov 19, 2021
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $24.7K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deluccia Robert JCIK 0001127423 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2021 | Common Stock | PPurchaseAcquired | +5,034 | $4.90F1 | +$24,666.6 | 1,031,461 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reflects the average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $4.886 to $4.961 per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price.
Referenced by the price of 1 transaction in Table I.
Remarks
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.